Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: vaccines - VLP Biotech

Drug Profile

Research programme: vaccines - VLP Biotech

Alternative Names: Allergy vaccine - VLP Biotech; Alzheimer's disease vaccine - VLP Biotech; Atherosclerosis vaccine - VLP Biotech; Cancer vaccine - VLP Biotech; Hepatitis B viral vaccine- VLP Biotech; Hepatitis C virus vaccine - VLP Biotech; Hypersensitivity vaccine - VLP Biotech; Influenza A virus vaccine - VLP Biotech; Lipid disorder vaccine - VLP Biotech; Malaria vaccine - VLP Biotech; Obesity vaccine - VLP Biotech; palivizumab epitope-displaying VLPs; RSV vaccine - VLP Biotech; VLP 206; VLP-162

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ChronTech Pharma; Vaccine Research Institute of San Diego
  • Developer AstraZeneca; VLP Biotech
  • Class Virus-like particle vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Hepatitis B; Malaria; Respiratory syncytial virus infections

Highest Development Phases

  • No development reported Anthrax; Hepatitis B; Malaria; Respiratory syncytial virus infections
  • Discontinued Alzheimer's disease; Atherosclerosis; Cancer; Hepatitis C; Hypersensitivity; Influenza virus infections; Lipid metabolism disorders; Obesity

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for preclinical development in Hepatitis-B in USA
  • 28 Jul 2023 No recent reports of development identified for preclinical development in Malaria in USA
  • 24 Feb 2021 Preclinical development for Malaria is ongoing in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top